You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

shr-1210

Showing 1 - 25 of 46
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Advanced Tumors Trial (SHR-1210)

Not yet recruiting
  • Advanced Tumors
  • SHR-1210
  • (no location specified)
Apr 4, 2023

Recurrent or Metastatic Cervical Cancer Trial in Shanghai (SHR-1210, SHR-1020, Physician's choice chemo)

Active, not recruiting
  • Recurrent or Metastatic Cervical Cancer
  • SHR-1210
  • +2 more
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Nov 14, 2022

Advanced Primary Liver Cancer, Advanced Biliary Tract Carcinoma Trial in Zhengzhou, Nanjing (SHR-1210, Apatinib, FOLFOX4)

Active, not recruiting
  • Advanced Primary Liver Cancer
  • Advanced Biliary Tract Carcinoma
  • SHR-1210
  • +3 more
  • Zhengzhou, Henan, China
  • +1 more
Apr 26, 2022

Nasopharyngeal Carcinoma Trial in Guangzhou (SHR-1210)

Completed
  • Nasopharyngeal Carcinoma
  • SHR-1210
  • Guangzhou, Guangdong, China
    Cancer Center of Sun-Yat Sen University (CCSYSU)
Apr 1, 2022

Gastric Cancer, GastroEsophageal Cancer Trial in China (SHR-1210, Capecitabine, Oxaliplatin)

Completed
  • Gastric Cancer
  • GastroEsophageal Cancer
  • SHR-1210
  • +3 more
  • Hefei, Anhui, China
  • +9 more
Jun 30, 2022

Hodgkin Lymphoma, Adult Trial in Beijing (SHR-1210)

Completed
  • Hodgkin Lymphoma, Adult
  • SHR-1210
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Oct 29, 2021

Renal Cell Carcinoma, Urothelial Carcinoma, Cervical Cancer Trial in Shanghai (SHR-1210, Famitinib)

Recruiting
  • Renal Cell Carcinoma
  • +4 more
  • Shanghai, Shanghai, China
    Huadong Hospital Affiliated to Fudan University
Jun 30, 2022

Gastric Cancer, GastroEsophageal Cancer Trial in Beijing (SHR-1210, Capecitabine, Oxaliplatin)

Active, not recruiting
  • Gastric Cancer
  • GastroEsophageal Cancer
  • SHR-1210
  • +3 more
  • Beijing, Beijing, China
    Beijing Cancer Hospital, Peking University
Aug 24, 2021

Advanced Hepatocellular Carcinoma Trial in Nanjing (SHR-1210, FOLFOX4, Placebo)

Recruiting
  • Advanced Hepatocellular Carcinoma
  • SHR-1210
  • +2 more
  • Nanjing, Jiangsu, China
    81 Hospital Nanjing
Feb 9, 2022

Recurrent Cervical Carcinoma, Metastatic Cervical Cancer Trial in Guangzhou, Guanzhou (SHR-1210, Apatinib)

Active, not recruiting
  • Recurrent Cervical Carcinoma
  • Metastatic Cervical Cancer
  • Guangzhou, Guangdong, China
  • +2 more
Sep 24, 2021

Locally Advanced Resectable Esophageal Squamous Cell Carcinoma Trial in Shanghai (SHR-1210)

Not yet recruiting
  • Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
  • SHR-1210
  • Shanghai, Shanghai, China
    Shanghai Chest Hospital
Sep 5, 2021

Lung Tumors Trial in Hangzhou (SHR-1210, BP102)

Terminated
  • Lung Neoplasms
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
Mar 15, 2021

Extensive Stage Small Cell Lung Cancer Trial (SHR-1210)

Not yet recruiting
  • Extensive Stage Small Cell Lung Cancer
  • SHR-1210
  • (no location specified)
Mar 7, 2021

Resectable Esophageal Squamous Cell Carcinoma Trial (SHR-1210)

Not yet recruiting
  • Resectable Esophageal Squamous Cell Carcinoma
  • SHR-1210
  • (no location specified)
Aug 17, 2021

Breast Cancer Trial in Guangzhou (SHR-1210, Apatinib)

Completed
  • Breast Cancer
  • Guangzhou, Guangdong, China
    Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Oct 21, 2020

Esophageal Tumors, Esophageal Diseases, Esophageal Squamous Cell Carcinoma Trial in Hangzhou (Radiation, SHR-1210)

Completed
  • Esophageal Neoplasms
  • +2 more
  • Hangzhou, Zhejiang, China
    Hangzhou Cancer Hospital
Aug 13, 2020

NSCLC Trial (SHR-1210, Apatinib)

Not yet recruiting
  • NSCLC
  • (no location specified)
Sep 5, 2020

Extranodal NK/T-cell Lymphoma, Nasal Type Trial in Zhengzhou (SHR-1210)

Unknown status
  • Extranodal NK/T-cell Lymphoma, Nasal Type
  • SHR-1210
  • Zhengzhou, Henan, China
    First Affiliated Hospital of Zhengzhou University
Jun 17, 2020

Colorectal Cancer Trial (SHR-1210, AIN 457)

Not yet recruiting
  • Colorectal Cancer
  • SHR-1210
  • AIN 457
  • (no location specified)
Mar 12, 2020

Lung Cancer Trial in Guangzhou (SHR-1210)

Completed
  • Lung Cancer
  • SHR-1210
  • Guangzhou, Guangdong, China
    Cancer hospital affiliated to Zhongshan University
Apr 8, 2020

Lung Tumors, NSCLC, Respiratory Tract Tumors Trial in Shanghai (SHR-1210, Carboplatin, Pemetrexed)

Completed
  • Lung Neoplasms
  • +8 more
  • SHR-1210
  • +2 more
  • Shanghai, Shanghai, China
    Tongji University, Shanghai Pulmonary Hospital
Jun 7, 2020

Rectal Cancer Trial in Beijing (drug, radiation, procedure)

Unknown status
  • Rectal Cancer
  • SHR-1210
  • +4 more
  • Beijing, China
    Beijing Cancer Hospital
Jul 8, 2020

Lung Cancer Squamous Cell, Lung Cancer Stage IV, PD-1 Antibody Trial in China (SHR-1210, The )

Active, not recruiting
  • Lung Cancer Squamous Cell
  • +3 more
  • SHR-1210
  • The placebo
  • Hefei, Anhui, China
  • +52 more
Mar 12, 2021

Progression-free Survival, Overall Survival, Clinical Benefit Rate Trial in Beijing (Apatinib, SHR-1210)

Completed
  • Progression-free Survival
  • +3 more
  • Beijing, China
  • +1 more
May 15, 2020

Non-Small-Cell Lung Cancer Trial in Jinan (SHR-1210)

Unknown status
  • Non-Small-Cell Lung Cancer
  • SHR-1210
  • Jinan, Shandong, China
    Shandong Cancer Hospital and Institute
Feb 3, 2020